Sector News

Novartis buys 12.8 percent stake in BioLineRX in co-development deal

December 17, 2014
Life sciences
(Reuters) – Swiss drugmaker Novartis AG bought a 12.8 percent stake in Israeli biopharmaceutical company BioLineRX Ltd as part of a multi-year collaboration deal, BioLineRX said on Tuesday.
 
Under the agreement, Novartis, which invested an initial $10 million, will evaluate projects presented by BioLineRX for development and future licensing, the Israeli firm said in a statement. They hope to develop up to three clinical projects.
 
Novartis acquired an initial 5 million American depositary shares of BioLineRx in a private transaction at $2.00 a share.
 
The partnership will be transformative for BioLineRX, said Chief Executive Kinneret Savitsky, and will give Novartis, one of the world’s largest pharmaceutical companies, access to Israeli research institutions, hospitals and biotech start-ups.
 
Once a project is selected, Novartis will pay BioLineRx an option fee of $5 million and fund half the remaining development costs in the form of an additional equity investment in BioLineRx.
 
The companies agreed to limit how big a share Novartis can buy of BioLineRX, but the amount was not disclosed, a BioLineRX spokeswoman said.
 
Novartis will have an exclusive right of first negotiation to license from BioLineRx each project.
 
(Reporting by Ari Rabinovitch; Editing by Tova Cohen and David Holmes)

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”